[HTML][HTML] Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
Z Zhu, H Tang, J Ying, Y Cheng, X Wang… - Cancer Biology & …, 2023 - ncbi.nlm.nih.gov
Objective: Gemcitabine plus nab-paclitaxel (GnP) is the standard first-line therapy for
advanced pancreatic ductal adenocarcinoma (PDAC). S-1, an oral fluoropyrimidine …
advanced pancreatic ductal adenocarcinoma (PDAC). S-1, an oral fluoropyrimidine …
Efficacy and safety of nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine for first-line chemotherapy in advanced pancreatic ductal adenocarcinoma
Y Zong, Z Peng, X Wang, M Lu, L Shen… - Cancer Management …, 2020 - Taylor & Francis
Objective Nab-paclitaxel plus gemcitabine (nab-P/G) has been established as a standard
first-line treatment in metastatic pancreatic ductal adenocarcinoma (PDAC). S-1, as an oral …
first-line treatment in metastatic pancreatic ductal adenocarcinoma (PDAC). S-1, as an oral …
Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized …
Y Zong, J Yuan, Z Peng, M Lu, X Wang, L Shen… - Journal of Cancer …, 2021 - Springer
Purpose To investigate the efficacy and safety of nab-paclitaxel plus S-1 (nab-P/S) versus
nab-paclitaxel plus gemcitabine (nab-P/G) as first-line chemotherapy in patients with …
nab-paclitaxel plus gemcitabine (nab-P/G) as first-line chemotherapy in patients with …
Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
JE Rogers, JD Mizrahi, L Xiao, C Mohindroo… - Cancer …, 2020 - Wiley Online Library
Background Gemcitabine (GEM) plus nab‐paclitaxel (NabP)(GEM 1000 mg/m2 IV over 30
minutes+ NabP 125 mg/m2 IV given days 1, 8, and 15 every 28 days) is one of the two …
minutes+ NabP 125 mg/m2 IV given days 1, 8, and 15 every 28 days) is one of the two …
[HTML][HTML] Combination of gemcitabine, nab-paclitaxel, and S-1 (GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal …
C Chang, X Li, D Cao - BMC cancer, 2021 - Springer
Background Pancreatic ductal adenocarcinoma (PDAC) is still a highly fatal malignancy
among the most common cancers. More powerful treatments are expecting to bring hope for …
among the most common cancers. More powerful treatments are expecting to bring hope for …
[HTML][HTML] Evaluation of early prognostic factors in patients with pancreatic ductal adenocarcinoma receiving gemcitabine together with nab-paclitaxel
W Izumo, R Higuchi, T Furukawa… - Cancer diagnosis & …, 2021 - ncbi.nlm.nih.gov
Background Gemcitabine together with nab-paclitaxel (GnP) has been shown to improve
outcomes in patients with pancreatic ductal adenocarcinoma (PDAC). However, the …
outcomes in patients with pancreatic ductal adenocarcinoma (PDAC). However, the …
State of the art and future directions of pancreatic ductal adenocarcinoma therapy
C Neuzillet, A Tijeras-Raballand, P Bourget… - Pharmacology & …, 2015 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second cause of
cancer-related death in 2030. PDAC is the poorest prognostic tumor of the digestive tract …
cancer-related death in 2030. PDAC is the poorest prognostic tumor of the digestive tract …
[HTML][HTML] Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma
A Bullock, K Stuart, S Jacobus, T Abrams… - Journal of …, 2017 - ncbi.nlm.nih.gov
Background There are limited treatment options available for patients with advanced
pancreatic ductal adenocarcinoma (PDAC). We conducted a phase II study evaluating the …
pancreatic ductal adenocarcinoma (PDAC). We conducted a phase II study evaluating the …
[HTML][HTML] Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
H Blomstrand, U Scheibling, C Bratthäll, H Green… - BMC cancer, 2019 - Springer
Background In the recent phase III trial MPACT the combination of gemcitabine and nab-
paclitaxel (Gem/NabP) showed increased overall survival compared to gemcitabine alone in …
paclitaxel (Gem/NabP) showed increased overall survival compared to gemcitabine alone in …
Gemcitabine with nab-paclitaxel in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A quality of life randomized cross-over …
G Chiritescu, K Dumon, C Verslype… - Annals of …, 2018 - annalsofoncology.org
Methods: In an academic multicentric phase II study, patients with locally advanced or
metastatic PDAC were randomized to receive gemcitabine 1000mg/m2 alone or with nab …
metastatic PDAC were randomized to receive gemcitabine 1000mg/m2 alone or with nab …
